The INPPL1 Knockout A-549 Polyclonal Cells represent a CRISPR/Cas9-edited polyclonal cell population derived from the A-549 human lung adenocarcinoma cell line. These cells carry a heterogeneous array of loss-of-function mutations in the INPPL1 gene, generated by CRISPR/Cas9-mediated gene disruption, resulting in a functional knockout model for studying INPPL1-dependent signaling pathways. The polyclonal format provides a population-level average of diverse knockout events, suitable for assessing the overall impact of INPPL1 deficiency without clonal selection bias.
The A-549 cell line is an epithelial cell model originating from a 58-year-old male patient with lung adenocarcinoma. It harbors a KRAS G12S activating mutation and retains wild-type p53, making it a widely employed system for investigating KRAS-driven oncogenic signaling and alveolar epithelial biology. A-549 cells are frequently utilized as a model of type II alveolar epithelium and are responsive to growth factor stimulation, rendering them suitable for dissecting pathways linked to cell proliferation, survival, and migration.
INPPL1 encodes SHIP2, a phosphatidylinositol 5-phosphatase that dephosphorylates PIP3 to PI(3,4)P2, thereby attenuating PI3K/AKT signaling. Upstream, SHIP2 is regulated by growth factor receptors including the insulin receptor, EGFR, and IGF1R. Downstream, loss of SHIP2 activity elevates PIP3 levels, leading to constitutive AKT phosphorylation and sustained activation of mTOR, GSK3??, and FOXO transcription factors. Additionally, SHIP2 interacts with scaffold proteins like p130Cas, filamin, c-Cbl, PI3K p85, SHC, and Grb2, coupling PI3K signaling to focal adhesion dynamics and actin cytoskeleton reorganization. Disruption of INPPL1 eliminates SHIP2-dependent PIP3 turnover, resulting in hyperactivation of the PI3K/AKT/mTOR cascade and altered cellular responses.
In the A-549 lung adenocarcinoma background with oncogenic KRAS G12S, INPPL1 knockout intensifies PI3K/AKT signaling, potentially cooperating with KRAS to drive proliferation and survival. This model is therefore suited for studying crosstalk between RAS-MAPK and PI3K pathways, as well as for identifying synthetic lethal interactions. Moreover, given SHIP2??s role in insulin signaling, these cells are useful for investigating insulin resistance and metabolic dysregulation in type 2 diabetes and metabolic syndrome. The polyclonal knockout A-549 cells also enable studies of cell migration and invasion through SHIP2??s associations with p130Cas and filamin at focal adhesions.
Researchers can employ the INPPL1 Knockout A-549 Polyclonal Cells in a broad range of functional assays to interrogate PI3K/AKT-dependent processes. Western blotting for phospho-AKT (Ser473 and Thr308) and phospho-signaling arrays can validate pathway hyperactivation, while cell proliferation and migration/invasion assays quantify phenotypic consequences of SHIP2 loss. Glucose uptake assays and RT-qPCR analysis of AKT target genes, such as those encoding GLUT4 translocation regulators, provide metabolic readouts. These applications support drug target validation efforts aimed at identifying novel inhibitors of the PI3K pathway or exploring adaptive resistance mechanisms. For further information, please contact Ascent Research.
